Merit Medical Systems reported second-quarter 2026 results with revenue of $418.8M and diluted EPS of $0.65, reflecting year-over-year growth in sales and profitability driven by broad product demand and operational improvements.
Financial Highlights
- Revenue was $418.8M, compared with $382.5M in the prior-year quarter; YoY change 9.5%.
- Net income was $38.8M, compared with $32.6M in the prior-year quarter; YoY change 19.1%.
- Diluted EPS was $0.65, compared with $0.54 in the prior-year quarter; YoY change 20.4%.
Business Highlights
- Revenue growth: Sales rose 9.5% in Q2 and 8.5% year-to-date, supported by strong demand across domestic and international markets.
- Channel & product mix: Foundational product sales increased 7.1% and Therapeutic sales climbed 14.8% in Q2, with notable gains in Cardiac, Endoscopy and OEM platforms.
- Brand momentum & M&A: Completed the View Point (OneMark) acquisition in April 2026 and integrated C2 Cryoballoon and Biolife assets to expand the product portfolio.
- Operational execution: Gross margin improved to about 51.4% driven by favorable mix and IEEPA tariff refunds; inventory was increased proactively to support service levels.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.